Previous close | 19.57 |
Open | 19.65 |
Bid | 19.41 x 0 |
Ask | 19.48 x 0 |
Day's range | 17.08 - 19.65 |
52-week range | 13.80 - 29.42 |
Volume | |
Avg. volume | 3 |
Market cap | 1.826B |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock is trading down after the company announced a regulatory update for Kresladi (marnetegragene autotemcel; marne-cel), a lentiviral (LV) vector-based gene therapy to treat severe leukocyte adhesion deficiency-I (LAD-I). The FDA has issued a Complete Response Letter (CRL) to Rocket’s Biologics License Application for Kresladi, in which the FDA requested limited additional Chemistry Manufacturing and Controls (CMC) information to complete its review. Ro
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...